78920-11-3

Basic information

• Product Name: 4-phenyl-5-hydroxy-2-(5H)-furanone
• Synonyms: 4-phenyl-5-hydroxy-2-(5H)-furanone
• CAS NO: 78920-11-3
• Molecular Weight: 176.172
• Mol File: 78920-11-3.mol

Chemical Properties

• CAS DataBase Reference: 4-phenyl-5-hydroxy-2-(5H)-furanone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenyl-5-hydroxy-2-(5H)-furanone(78920-11-3)
• EPA Substance Registry System: 4-phenyl-5-hydroxy-2-(5H)-furanone(78920-11-3)

Safety Data

• Hazardous Substances Data: 78920-11-3(Hazardous Substances Data)

Upstream product

• 122-78-1 phenylacetaldehyde 
• 298-12-4 Glyoxilic acid 
• 563-96-2 2,2-dihydroxyacetic acid 
• 78939-67-0 5-Morpholin-4-yl-4-phenyl-5H-furan-2-one 
• 914362-10-0 4-phenyl-5-(tetrahydro-pyran-2-yloxy)-5H-furan-2-one 
• 98-80-6 phenylboronic acid 
• 78920-17-9 3-phenyl-4-ethoxy-2-butenolide 

Downstream Products

• 1575-47-9 4-phenyl-5H-furan-2-one 
• 78920-21-5 5-phenylpyridazin-3(2H)-one 
• 5676-35-7 3-Phenylsuccinaldehydic acid 
• 78920-22-6 5-hydroxy-4-phenyl-4,5-dihydro-3H-furan-2-one 
• 1008-73-7 4-phenyldihydrofuran-2(3H)-one 
• 99389-53-4 (E)-4-Hydroxy-3-phenyl-but-2-enoic acid 
• 40951-19-7 sodium 4-hydroxy-3-phenylbutanoate 
• 78920-27-1 5-ethoxy-4,5-dihydro-4-phenylfuran-2(3H)-one 
• 105537-97-1 5-phenylpyridazine-3-amine 
• 100079-09-2 3-hydrazino-5-phenylpyridazine 
• 86663-08-3 3-chloro-5-phenyl-pyridazine 
• 105538-14-5 6-Amino-1-(3-ethoxycarbonyl-propyl)-4-phenyl-pyridazin-1-ium; bromide 
• 78920-21-5 5-phenylpyridazin-3-ol 

Relevant articles and documents

PPAR-gamma ACTIVATOR

The present invention provides A PPARγ activator comprising a butenolide compound represented by the formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, a phosphate group, a fatty acid group, an alk

Regioselective entry to bromo-γ-hydroxybutenolides: Useful building blocks for assemblying natural product-like libraries

(Chemical Equation Presented) We report a regioselective entry to 3-bromo- and 4-bromo-5-hydroxy-5H-furan-2-ones by photooxidation of 3-bromofuran with a singlet oxygen in the presence of a suitable base. By this procedure, a variety of 3-substituted γ-hydroxybutenolides have become for the first time easily accessible. Strategies employing these highly functionalized building blocks for the preparation of focused libraries of natural-like molecules are also discussed.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

4-ARYL- AND 4-ARYLTHIO-5-HYDROXY-2(5H)-FURANONES AS INHIBITORS OF PHOSPHOLIPASE A2

The invention provides novel 5-hydroxy-4-aryl- and 5-hy-droxy-4-(arylthio)-2(5H)-furanones of the following structure: wherein R contains from about five to about twenty carbon atoms and is defined herein; X is oxygen, sulfur, S02, NH, N(lower alkyl), N(lower acyl), aminocarbonyl, carbonyl, carbonylamino, CH2 or a carbon-carbon bond; Y is hydrogen, halogen, lower alkyl, nitro, alkylthio, perfluoroalkyl, hydroxy, or lower alkoxy(C1-C8); Z is sulfur or a carbon-carbon bond; and Q is H, an alkyl of from 1-20 carbon atoms, COR', COOR', CONHR', PO(OR')2, PO(OR')R" wherein R' and R" are independently selected from the group consisting of H, an alkyl of from 1-20 carbon atoms, phenyl, and substituted phenyl and prodrugs thereof and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising these compounds, methods of using these compounds as inhibitors of inflammation and for treating other diseases characterized by the overproduction of arachidonic acid metabolites, intermediates and methods of preparing these compounds are also provided.

Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists

We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.

Lactone Chemistry. Synthesis of β-Substituted, γ-Functionalized Butanolides and Butenolides and Succinaldehydic Acids from Glyoxylic Acid

The Mannich-type aminoalkylation reaction of enolizable aldehydes with morpholine and glyoxylic acid instead of formaldehyde was investigated: in basic and neutral media were obtained α,γ-dimorpholinobutanolides 2 and α-morpholino-γ-hydroxybutanolides 1, respectively.In acidic medium the spontaneous elimination of the α-morpholino group afforded the γ-hydroxybutenolide 8.The reaction pathways were suggested from the isolation and characterization of some intermediates of the Mannich reaction.These lactone structures constitute versatile synthetic intermediates for the preparation of β-substituted succinaldehydic acids 15 and 5-substituted 3-(2H)-pyridazinones 13 and 14.